although less so initially to children and parents. It involves a general anaesthetic, surgical placement of a permanent device that can erode fragile skin, ongoing maintenance and a significant adjustment in body image. Is it worthwhile? The systematic review in the current issue of the British Journal of Dermatology by Zidorio et al. addresses this question.

Evaluation of therapy in this complex, heterogeneous, rare disease is difficult. There are no randomized controlled trials of GTT in EB: the seven suitable studies selected from a literature trawl of 641 were case series. Most involved children with RDEB and the authors included only studies providing anthropometric data and patient- or carer-reported outcomes. They conclude that nutritional status usually, but not always, improves. Interestingly, some patients report better life quality even when growth parameters have worsened, perhaps reflecting the extreme burden of maintaining oral intake. Effects on skin blistering, healing and activity levels are hard to quantify and are rarely documented. Complications led to GTT removal in 10% of patients. Unanswered questions include optimum diet and timing: should it be placed before or after malnutrition becomes a problem?

Surgical technique was not covered in this review, so failed procedures and immediate complications would not have been picked up. Endoscopic GTT placement risks mucosal damage, while placement via a laparotomy is invasive and likely to be complicated by chronic leakage. A laparoscopic approach has been used successfully.

Professionals managing EB need to share experience and collect consistent data on procedures, complications, nutritional status and EB-related quality of life. This can be achieved only if those managing patients with EB consult with expert centres, which in turn should collaborate. The organizations Debra International and EBClinet are leading the way in developing clinical practice guidelines. The U.K. has the unique advantage of a National Health Service and national Highly Specialized Service for EB: four of the seven studies came from U.K. centres but even these were not ideal. The newly established European Reference Network for Rare and Low Prevalence Complex Disease, with a specific sub-thematic group for EB, offers exciting opportunities for collaborative research, which patients and professionals sorely need.

Acknowledgments

The author would like to acknowledge Fiona Browne and Robin Ferner for their helpful critical reviews of this commentary.

Conflicts of interest

None to declare.

References

1 Zidorio APC, Dutra ES, Castro LCG, Carvalho KMB. Effectiveness of gastrostomy for improving nutritional status and quality of life in patients with epidermolysis bullosa: a systematic review. Br J Dermatol 2018; 179:42–9.

2 Hubbard LD, Mayre-Chilton K. Quality of life among adults with epidermolysis bullosa living with a gastrostomy tube since childhood. Qual Health Res 2015; 25:310–19.

3 Patel K, Wells J, Jones R et al. Use of a novel laparoscopic gastrostomy technique in children with severe epidermolysis bullosa. J Pediatr Gastroenterol Nutr 2014; 58:621–3.

4 Laimer M, Pohla-Gubo G, Diem A et al. Epidermolysis Bullosa House Austria and Epidermolysis Bullosa Clinical Network: example of a centre of expertise implemented in a European Reference Network to face the burden of a rare disease. Wim Klin Wochenschr 2017; 129:1–7.

5 See: http://www.debra-international.org/clinical-guidelines.html (last accessed 8 May 2018).

6 See: https://ec.europa.eu/health/ern/networks_en (last accessed 8 May 2018).

Supporting Information

Additional Supporting Information may be found in the online version of this article at the publisher’s website:

Audio S1. Author audio.

A pilot comparing ultraviolet modalities for hand eczema: shedding light on feasibility

DOI: 10.1111/bjd.16694

Linked Article: Brass et al. Br J Dermatol 2018; 179:63–71.

In this issue of the BJD, Brass and colleagues report the results of a pilot study in which they explore the feasibility of performing a large randomized controlled trial (RCT) comparing psoralen–ultraviolet A (PUVA) and narrowband ultraviolet B (NBUVB) for the treatment of chronic palmar hand eczema.

It is very important that pilot studies are carried out, both financially and methodically. A full-scale RCT will ideally be performed only if its design proves feasible in a pilot. Potential flaws can be identified and dealt with, increasing the chance of performing a meaningful definitive study with practical implications. However, one should be very careful about the interpretation of efficacy data from pilot studies. Because pilot studies often contain the first structured assessment of the effect of an intervention, no robust sample-size calculation can be performed a priori. No sound conclusions can be made based on an insufficient sample size. One can often only really draw conclusions regarding feasibility.

Brass et al.1 venture to make some cautious statements on efficacy outcomes. They conclude that both PUVA and NBUVB improve the severity of chronic palmar hand eczema. However, a few considerations put this conclusion in a different light.
The primary efficacy outcome measure used in the study is a Physician Global Assessment (PGA) that is used in a large placebo-controlled trial with the retinoid alitretinoin in hand eczema. This PGA incorporates not only objective signs like fissures and erythema, but also the subjective (patient-reported) items ‘pain’ and ‘itch’, which influence the severity score, making it hard to reproduce this outcome and making proper comparison between patients and between studies difficult. The authors argue that a more objective outcome like the Hand Eczema Severity Index (HECSI) might be a preferable alternative. Although true, it should be noted that this instrument needs to be validated more extensively before using it as primary efficacy outcome in trials. Furthermore, this pilot studied only patients with palmar hand eczema. A measurement instrument for the severity of solely palmar hand eczema has not yet been developed.

It is strongly recommended to patch test all patients with chronic hand eczema in routine daily practice. No patch testing was performed prior to this pilot. Because patients with hand eczema frequently have allergic contact dermatitis it is vital to take this into account. Patch testing will reduce the bias of inclusion of patients into studies while they still have major exposure to contact allergens that might be highly relevant for the severity of their hand eczema.

On the subject of feasibility, the authors see some issues. A large sample size will be needed for the definitive trial, while the rise of systemic therapy may lead to a reduced demand for phototherapy. Results of the ongoing ALPHA trial, comparing PUVA with alitretinoin for uncontrolled severe chronic hand eczema, will significantly influence whether there will be a need for a full-scale trial comparing PUVA with NBUVB. If such a need does arise, processing the issues mentioned above, along with the limitations that the authors state in their discussion will contribute to the design of a more comprehensive and meaningful clinical trial.

Acknowledgments
The author would like to acknowledge M.L.A. Schuttelaar and D. Dittmar for their critical revision of this commentary.

Conflicts of interest
None to declare.

References
1. Brass D, Fouweather T, Stocken DD et al. An observer-blinded randomized controlled pilot trial comparing localized immersion psoralen–ultraviolet A with localized narrowband ultraviolet B for the treatment of palmar hand eczema. Br J Dermatol 2018; 179: 63–71.
2. Eldridge SM, Chan CL, Campbell MJ et al. CONSORT 2010 statement: extension to randomised pilot and feasibility trials. BMJ 2016; 355: i5239.
3. Ruzicka T, Lynde CW, Jemec GB et al. Efficacy and safety of oral alitretinoin (9-cis retinoic acid) in patients with severe chronic hand eczema refractory to topical corticosteroids: results of a randomized, double-blind, placebo-controlled, multicentre trial. Br J Dermatol 2008; 158: 808–17.
4. Held E, Skoet R, Johansen JD, Agner T. The hand eczema severity index (HECSI): a scoring system for clinical assessment of hand eczema. A study of inter- and intraobserver reliability. Br J Dermatol 2005; 152: 302–7.
5. Diepgen TL, Andersen KF, Chosidow O et al. Guidelines for diagnosis, prevention and treatment of hand eczema. J Dtsch Dermatol Ges 2015; 13: e1–22.
6. Agner T, Aalto-Korte K, Andersen KF et al. Classification of hand eczema. J Eur Acad Dermatol Venereol 2015; 29: 2417–22.
7. Smith IL, Brown S, Nixon J et al. Treatment of severe, chronic hand eczema: results from a UK-wide survey. Clin Exp Dermatol 2017; 42: 185–8.

Supporting Information
Additional Supporting Information may be found in the online version of this article at the publisher’s website:
Audio S1. Author audio.

Aldara-induced dermatitis is associated with development of liver fibrosis in mice

DOI: 10.1111/bjd.16693

Linked Article: Vasseur et al. Br J Dermatol 2018; 179: 101–109.

Liver fibrosis is a wound-healing response that occurs secondary to insults from hepatocyte lipid accumulation, inflammation and exposure to toxins, such as methotrexate and alcohol. A 2017 population-based study (people with psoriasis: n = 197 130) supported what other studies have previously shown: people with severe psoriasis are more likely to have liver fibrosis and cirrhosis than age-, sex- and BMI matched controls in the general population.

Liver fibrosis is a multifactorial disease; therefore, in human studies it will always be a challenge to disentangle the relative weighting of multiple potential risks (burden of inflammation, alcohol, obesity) on fibrosis development and progression. One strength of animal studies is the ability to investigate the impact of one risk alone.

Does psoriasis cause liver fibrosis? In this issue of the BJD, Vasseur et al. publish data to suggest that, in mice, cutaneous inflammation induced by repetitive applications of imiquimod-containing Aldara cream is associated with the development of hepatitis and liver fibrosis. (In mice both the vehicle in Aldara and imiquimod contribute to inflammation.)

Vasseur et al. compared two groups of mice (n = 10 mice/group). The first group were exposed to Aldara over 9 weeks;